{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:30:24Z","timestamp":1792668624879,"version":"4.5.0"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"25","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2006,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100\/\u03bcL, prior AIDS, or performance status less than 2. This multicenter phase II trial evaluated the response rate and disease-free survival after six courses of rituximab plus CHOP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-one patients were enrolled. All the patients were assessable for safety and 52 were assessable for the tumor response after treatment completion. Characteristics of patients were median age, 41 years; median CD4 cells, 172\/\u03bcL; histology, diffuse large B-cell lymphoma (n = 42), immunoblastic (n = 2), Burkitt lymphoma (n = 16), and plasmablastic (n = 1); 42 patients with stage III to IV; International Prognostic Index 0 to 1 (n=31), and 2 to 3 (n = 27). Grade 3 or 4 toxicity consisted of febrile neutropenia in nine patients, anemia in 16 patients, and thrombocytopenia in five patients. Complete remission (CR) or unconfirmed CR was achieved in 40 of the 52 assessable patients, partial remission was achieved in five patients, and seven patients experienced progression. Forty-three patients were alive after a median follow-up of 33 months. The estimated 2-year overall survival rate was 75% (95% CI, 64% to 86%). Eighteen patients died: 16 as a result of lymphoma, one as a result of infection, and one as a result of encephalitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2005.05.4684","type":"journal-article","created":{"date-parts":[[2006,8,8]],"date-time":"2006-08-08T23:38:54Z","timestamp":1155080334000},"page":"4123-4128","source":"Crossref","is-referenced-by-count":170,"title":["Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"24","author":[{"given":"Fran\u00e7ois","family":"Bou\u00e9","sequence":"first","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gabarre","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gisselbrecht","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Cheret","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Billaud","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Raphael","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Lancar","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Costagliola","sequence":"additional","affiliation":[{"name":"From the Agence Nationale Recherche sur le Sida et les H\u00e9patites Paris; H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart; Universit\u00e9 Paris Sud; H\u00f4pital Salp\u00e9tri\u00e8re, Paris; H\u00f4pital Saint Louis, Paris; H\u00f2pital Gui de Chauliac, Montpellier; H\u00f4pital Gustave Dron, Tourcoing; H\u00f4pital Saint Andr\u00e9, Bordeaux; H\u00f4tel Dieu, Nantes; H\u00f4pital Bic\u00eatre, Le Kremlin Bic\u00eatre; INSERM U720 and Universit\u00e9 Pierre et Marie Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Lewden C, Salmon D, Morlat P, et al: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34:121,2005-130,","DOI":"10.1093\/ije\/dyh307"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.8.8"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90259-R"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3601"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01020-8"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362304"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3589"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"R12","unstructured":"Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.195"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3300"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1437"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.05.4684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T17:25:31Z","timestamp":1653499531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.05.4684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":18,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2006,9,1]]}},"alternative-id":["10.1200\/JCO.2005.05.4684"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.05.4684","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}